ARPA‑H awarded up to $31.7 million to a multi‑partner consortium led by Ginkgo Bioworks and AI discovery firm Deep Origin to develop non‑animal computational and ex‑vivo systems for drug safety and ADME‑Tox prediction. The PREDICTS consortium will integrate perturbation‑response profiling, DRUG‑seq transcriptomics and cell‑painting readouts to train digital models that aim to reduce reliance on preclinical animal studies. Consortium partners include Sanford Burnham Prebys, ImmVue Therapeutics and academic groups; Ginkgo will provide data generation and assay platforms while Deep Origin will supply digital modeling tools. The program intends to produce cell‑type‑specific toxicity endpoints and early human‑relevant dosing predictions. If successful, these models could accelerate early screening, lower attrition, and shift regulatory expectations for safety packages—though regulators will need to validate and accept surrogate outputs for pivotal decision‑making.